Nucleix expands EU label for bladder cancer test

By staff writers

June 22, 2022 -- Liquid biopsy firm Nucleix announced that it has expanded the European Union (EU) label indication of its EpiCheck test, which detects DNA methylation patterns in urine that are linked to urothelial cancer.

Initially, the technology was indicated for the monitoring of tumor recurrence in conjunction with cystoscopy in patients previously diagnosed with bladder cancer.

The update expands the label indication to include aiding in the detection of primary bladder cancer and upper tract urothelial carcinoma (UTUC) in patients with hematuria and/or other urinary tract symptoms and/or findings with a suspicion of malignancy.

It also includes the detection of recurrent UTUC in conjunction with standard diagnostic procedures.

Nucleix advances EpiCheck lung cancer platform
Nucleix has announced promising research findings in its EpiCheck next-generation sequencing platform for detecting early-stage lung cancer. The company...
Nucleix secures $55M in funding for lung cancer test
Liquid biopsy company Nucleix has secured $55 million to advance Lung EpiCheck, an early detection lung cancer test based on methylation technology.
Nucleix showcases Bladder EpiCheck at EAU 2020
Liquid biopsy firm Nucleix touted results for its methylation-based Bladder EpiCheck urine test in two presentations at the 2020 European Association...
Nucleix highlights data for urine test in detecting bladder cancer
Liquid biopsy firm Nucleix said that its methylation-based Bladder EpiCheck urine test produced strong results for detecting high-risk, non-muscle invasive...

Copyright © 2022

Last Updated mp 6/22/2022 1:44:59 PM